LEADER 01797nam  2200337   450 
001 9910714444903321
005 20230614222012.0
035   $a(CKB)3790000000049559
035   $a(NjHacI)993790000000049559
035   $a(EXLCZ)993790000000049559
100   $a20230614d2014      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFollow-On Biologics $ethe law and intellectual property issues /$fJohn R. Thomas
210  1$aWashington, District of Columbia :$cCongressional Research Service,$d2014.
215   $a1 online resource (21 pages)
225 0 $aCRS report for Congress
330   $aReviews intellectual property and innovations issues within context of the Biologics Price Competition and Innovation Act (BPCIA) of 2009, which established expedited licensor pathway for competing versions of previously marketed biologics, created FDA-administered periods of data protection and marketing exclusivity for certain brand-name drugs and follow-on products, and provided a patent dispute resolution procedure for use by brand-name and follow-on biologic manufacturers. Provides introduction to biologics industry, which includes biotechnology and biopharmaceutical industries; reviews regulatory and intellectual property provisions of BPCIA; and considers potential market for biosimilars and possible responses that may arise in wake of this legislation.
606   $aBiotechnology$xLaw and legislation
615  0$aBiotechnology$xLaw and legislation.
676   $a346.0486
700   $aThomas$b John R.$01362636
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910714444903321
996   $aFollow-On Biologics$93382092
997   $aUNINA